Desipramine (RX) : Interactions

1/10/2019 Norpramin (desipramine) dosing, indications, interactions, adverse effects, and more
This site is intended for healthcare professionals
desipramine (Rx)
Brand and Other Names: Norpramin
Classes: Antidepressants, TCAs
Interactions
Interaction Checker
Enter a drug name and desipramine

No Interactions Found
Interactions Found
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
All Interactions Sort By: Severity
Contraindicated (21)
cisapride
desipramine and cisapride both increase QTc interval. Contraindicated.
disopyramide
desipramine and disopyramide both increase QTc interval. Contraindicated.
dronedarone
dronedarone will increase the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Contraindicated. Increased potential risk of torsade's de
pointes-type ventricular tachycardia.
eliglustat
desipramine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism.

Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce
https://reference.medscape.com/drug/norpramin-desipramine-342939#3 1/59
eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate

metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given
concomitantly with strong or moderate CYP3A inhibitors.
flibanserin
desipramine will increase the level or effect of flibanserin by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate
or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.
ibutilide
desipramine and ibutilide both increase QTc interval. Contraindicated.
indapamide
desipramine and indapamide both increase QTc interval. Contraindicated.
iobenguane I 123
desipramine decreases effects of iobenguane I 123 by pharmacodynamic antagonism.

Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at
least 5 half-lives; may cause false-negative imaging results.
isocarboxazid
isocarboxazid and desipramine both increase serotonin levels. Contraindicated.
lomitapide
desipramine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Contraindicated. Increases lomitapide levels several folds.
pentamidine
desipramine and pentamidine both increase QTc interval. Contraindicated.
phenelzine
phenelzine and desipramine both increase serotonin levels. Contraindicated.
pimozide
desipramine and pimozide both increase QTc interval. Contraindicated.
procainamide
desipramine and procainamide both increase QTc interval. Contraindicated.
procarbazine
procarbazine and desipramine both increase serotonin levels. Contraindicated. Combination

is contraindicated within 2 weeks of MAOI use.
quinidine
quinidine and desipramine both increase QTc interval. Contraindicated.
safinamide
desipramine, safinamide. Either increases toxicity of the other by serotonin levels.

Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.
selegiline
selegiline and desipramine both increase serotonin levels. Contraindicated. Concurrent use
or use within 14 days of selegiline treatment is contraindicated
sotalol
desipramine and sotalol both increase QTc interval. Contraindicated.
thioridazine
thioridazine will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Contraindicated.
tranylcypromine
tranylcypromine and desipramine both increase serotonin levels. Contraindicated.
Serious - Use Alternative (137)
albuterol
desipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment:
Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking
reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amiodarone
desipramine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.
amitriptyline
amitriptyline and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
amitriptyline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
amoxapine
amoxapine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
arformoterol
desipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment:
arsenic trioxide
desipramine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.
artemether/lumefantrine
artemether/lumefantrine will increase the level or effect of desipramine by affecting hepatic

enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
desipramine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate
Drug.
axitinib
desipramine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate
CYP3A4 inhibitors, monitor closely and reduce dose if necessary .
benzphetamine
desipramine, benzphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment:
bosutinib
desipramine increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Avoid or Use Alternate Drug.
buspirone
desipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
chlorpromazine
chlorpromazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
citalopram
citalopram and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic
malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.
clarithromycin
clarithromycin will increase the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
desipramine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.
clomipramine
clomipramine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
clomipramine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
clonidine
desipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate
Drug. Comment: Inhibition of uptake by adrenergic neurons.
cobimetinib
desipramine will increase the level or effect of cobimetinib by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days
or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking
cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a
moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate
CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).
cyclobenzaprine
desipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate
Drug.
dacomitinib
dacomitinib will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates
where minimal increases in concentration of the CYP2D6 substrate may lead to serious or
life-threatening toxicities.
dasatinib
dasatinib will increase the level or effect of desipramine by affecting hepatic/intestinal

desvenlafaxine
desipramine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
dexfenfluramine
desipramine, dexfenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment:
dexmethylphenidate
desipramine, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug.

Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by
blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic
neuron.
dextroamphetamine
desipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug.

neuron.
dextromethorphan
desipramine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate
Drug.
diethylpropion
desipramine, diethylpropion. Other (see comment). Avoid or Use Alternate Drug. Comment:
dobutamine
desipramine, dobutamine. Other (see comment). Avoid or Use Alternate Drug. Comment:
dofetilide
desipramine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.
dolasetron
dolasetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or
Use Alternate Drug.
dopamine
desipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment:
dopexamine
desipramine, dopexamine. Other (see comment). Avoid or Use Alternate Drug. Comment:
dosulepin
desipramine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.
doxepin
desipramine and doxepin both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.
dronedarone
desipramine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.
droperidol
desipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
duloxetine
duloxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
eliglustat
desipramine increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not
recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from
84 mg BID to 84 mg once daily in extensive metabolizers .
entrectinib
desipramine will increase the level or effect of entrectinib by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of
moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration
unavoidable, reduce dose to 200 mg/day for patients aged 12 y or older with BSA >1.50m2.
Resume previous entrectinib dose after discontinuing moderate CYP3A inhibitor for 3-5
elimination half-lives.
ephedrine
desipramine, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment:
ephedrine (pulmonary)
desipramine, ephedrine (pulmonary). Other (see comment). Avoid or Use Alternate Drug.
neuron.
epinephrine
epinephrine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine, epinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment:
epinephrine racemic
epinephrine racemic and desipramine both increase QTc interval. Avoid or Use Alternate
Drug.
desipramine, epinephrine racemic. Other (see comment). Avoid or Use Alternate Drug.
neuron.
erythromycin base
erythromycin base will increase the level or effect of desipramine by affecting

hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
desipramine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
erythromycin ethylsuccinate
erythromycin ethylsuccinate will increase the level or effect of desipramine by affecting

desipramine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use
Alternate Drug.
erythromycin lactobionate
erythromycin lactobionate will increase the level or effect of desipramine by affecting

desipramine and erythromycin lactobionate both increase QTc interval. Avoid or Use
Alternate Drug.
erythromycin stearate
erythromycin stearate will increase the level or effect of desipramine by affecting

desipramine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate
Drug.
escitalopram
escitalopram and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
fenfluramine
desipramine, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment:
fentanyl
desipramine will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors
with fentanyl is necessary, monitor patients for respiratory depression and sedation at
frequent intervals and consider fentanyl dose adjustments until stable drug effects are
achieved.
fentanyl intranasal
desipramine will increase the level or effect of fentanyl intranasal by affecting

hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If
coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for
respiratory depression and sedation at frequent intervals and consider fentanyl dose
adjustments until stable drug effects are achieved.
fentanyl iontophoretic transdermal system
desipramine will increase the level or effect of fentanyl iontophoretic transdermal system by
affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If
fentanyl transdermal
desipramine will increase the level or effect of fentanyl transdermal by affecting

fentanyl transmucosal
desipramine will increase the level or effect of fentanyl transmucosal by affecting

fluconazole
fluconazole will increase the level or effect of desipramine by affecting hepatic/intestinal

desipramine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
fluoxetine
fluoxetine will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Avoid or Use Alternate Drug.
fluoxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
fluphenazine
fluphenazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
fluvoxamine
fluvoxamine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
formoterol
desipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
desipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment:
fosamprenavir
fosamprenavir increases levels of desipramine by decreasing metabolism. Avoid or Use

Alternate Drug.
granisetron
granisetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or
Use Alternate Drug.
guanfacine
desipramine decreases effects of guanfacine by Other (see comment). Avoid or Use

Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
haloperidol
haloperidol will increase the level or effect of desipramine by affecting hepatic enzyme
desipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.
imipramine
desipramine and imipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.
iobenguane I 131
desipramine will decrease the level or effect of iobenguane I 131 by Other (see comment).
Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that
reduce catecholamine uptake or that deplete catecholamine stores may interfere with
iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering
drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane
dose. Do not administer these drugs until at least 7 days after each iobenguane dose.
isoproterenol
desipramine, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment:
ivabradine
desipramine will increase the level or effect of ivabradine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of
ivabradine with moderate CYP3A4 inhibitors.
ivosidenib
ivosidenib and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid
coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies.
If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc
interval prolongation.
ketoconazole
desipramine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
levalbuterol
desipramine, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment:
levomilnacipran
levomilnacipran and desipramine both increase serotonin levels. Avoid or Use Alternate
Drug.
linezolid
linezolid and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be
administered, discontinue serotonergic drug immediately and monitor for CNS toxicity.
Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of
monitoring, whichever comes first.
lisdexamfetamine
desipramine, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug.

neuron.
lofepramine
desipramine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug.
lorcaserin
desipramine and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.
lumefantrine
lumefantrine will increase the level or effect of desipramine by affecting hepatic enzyme
desipramine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
macimorelin
macimorelin and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid
coadministration with drugs that prolong QT interval, which could increase risk for developing
torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that
are known to prolong the QT interval before administering macimorelin.
maprotiline
desipramine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.
meperidine
desipramine and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.
metaproterenol
desipramine, metaproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment:
methamphetamine
desipramine, methamphetamine. Other (see comment). Avoid or Use Alternate Drug.

neuron.
methylene blue
methylene blue and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue
must be administered, discontinue serotonergic drug immediately and monitor for CNS
toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or
after 2 weeks of monitoring, whichever comes first.
methylenedioxymethamphetamine
desipramine, methylenedioxymethamphetamine. Other (see comment). Avoid or Use

Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of
sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect
sympathomimetics into the adrenergic neuron.
midazolam intranasal
desipramine will increase the level or effect of midazolam intranasal by affecting

Coadministration of strong CYP3A4 inhibitors with midazolam intranasal causes higher
midazolam systemic exposure, which may prolong sedation.
midodrine
desipramine, midodrine. Other (see comment). Avoid or Use Alternate Drug. Comment:
milnacipran
milnacipran and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
moxifloxacin
desipramine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
naloxegol
desipramine will increase the level or effect of naloxegol by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministation of naloxegol
with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay
nefazodone
nefazodone will increase the level or effect of desipramine by affecting hepatic/intestinal

nefazodone and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
neratinib
desipramine will increase the level or effect of neratinib by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of neratinib with
strong/moderate CYP3A4 inhibitors.
netupitant/palonosetron
netupitant/palonosetron, desipramine. Either increases toxicity of the other by serotonin

levels. Avoid or Use Alternate Drug.
nilotinib
desipramine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.
norepinephrine
desipramine, norepinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment:
nortriptyline
desipramine and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug.
octreotide
desipramine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
octreotide (Antidote)
desipramine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate
Drug.
olaparib
desipramine will increase the level or effect of olaparib by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A
inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet)
PO BID. Do not substitute tablets with capsules.
ondansetron
desipramine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid
with congenital long QT syndrome; ECG monitoring recommended with concomitant
medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
ondansetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or
Use Alternate Drug.
palonosetron
palonosetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or
Use Alternate Drug.
paroxetine
paroxetine will increase the level or effect of desipramine by affecting hepatic enzyme
paroxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
perphenazine
perphenazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
phendimetrazine
desipramine, phendimetrazine. Other (see comment). Avoid or Use Alternate Drug.

neuron.
phentermine
desipramine, phentermine. Other (see comment). Avoid or Use Alternate Drug. Comment:
phenylephrine
desipramine, phenylephrine. Other (see comment). Avoid or Use Alternate Drug. Comment:
phenylephrine PO
desipramine, phenylephrine PO. Other (see comment). Avoid or Use Alternate Drug.
neuron.
pirbuterol
desipramine, pirbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment:
pitolisant
desipramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate
Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor
antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.
promazine
promazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
propylhexedrine
desipramine, propylhexedrine. Other (see comment). Avoid or Use Alternate Drug. Comment:
protriptyline
desipramine and protriptyline both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug.
pseudoephedrine
desipramine, pseudoephedrine. Other (see comment). Avoid or Use Alternate Drug.

neuron.
quinidine
quinidine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6
metabolism. Avoid or Use Alternate Drug.
rasagiline
rasagiline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
Severe CNS toxicity associated with hyperpyrexia has been reported with the combined
treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI
use.
salmeterol
desipramine, salmeterol. Other (see comment). Avoid or Use Alternate Drug. Comment:
selegiline transdermal
selegiline transdermal and desipramine both increase serotonin levels. Avoid or Use
Alternate Drug.
sertraline
sertraline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
siponimod
desipramine will increase the level or effect of siponimod by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod
with a moderate or strong CYP3A4 inhibitor PLUS a moderate or strong CYP2C9 inhibitor is
not recommended.
sodium oxybate
desipramine, sodium oxybate. Either increases effects of the other by pharmacodynamic

synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma,
and death may result if coadministered. Reserve concomitant prescribing of these drugs in
patients for whom other treatment options are inadequate. Limit dosages and durations to the
minimum required. Monitor closely for signs of respiratory depression and sedation.
St John's Wort
desipramine and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.
tedizolid
tedizolid, desipramine. Either increases effects of the other by Mechanism:

pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels;
increased risk of serotonin syndrome.
terbutaline
desipramine, terbutaline. Other (see comment). Avoid or Use Alternate Drug. Comment:
thioridazine
thioridazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
toremifene
desipramine and toremifene both increase QTc interval. Avoid or Use Alternate Drug.
Concurrent use of toremifene with agents causing QT prolongation should be avoided. If
concomitant use is required it's recommended that toremifene be interrupted. If interruption
not possible, patients requiring therapy with a drug that prolongs QT should be closely
monitored. ECGs should be obtained for high risk patients.
trazodone
desipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
trifluoperazine
trifluoperazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
trimipramine
desipramine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.
umeclidinium bromide/vilanterol inhaled

desipramine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval.

Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with
drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may
be potentiated.
desipramine and umeclidinium bromide/vilanterol inhaled both increase sympathetic

(adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use
Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or
within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the
cardiovascular system may be potentiated
vandetanib
desipramine, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use
Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug
known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
vemurafenib
vemurafenib and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
venetoclax
desipramine will increase the level or effect of venetoclax by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If a moderate CYP3A inhibitor
must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of
venetoclax toxicities.
venlafaxine
venlafaxine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
vilanterol/fluticasone furoate inhaled
desipramine and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic)

effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug.
Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks
of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system
may be potentiated
desipramine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid

or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs
that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be
potentiated.
vilazodone
desipramine, vilazodone. Either increases toxicity of the other by serotonin levels. Avoid or
Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or
symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be
initiated. .
vortioxetine
desipramine increases toxicity of vortioxetine by serotonin levels. Avoid or Use Alternate

Drug.
xylometazoline
desipramine, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment:
yohimbe
yohimbe, desipramine. Mechanism: unspecified interaction mechanism. Contraindicated.

May cause increase or decrease in blood pressure.
yohimbine
desipramine, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment:
ziprasidone
desipramine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (345)
5-HTP
desipramine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.
abiraterone
abiraterone increases levels of desipramine by affecting hepatic enzyme CYP2D6

metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of
CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose
reduction of the CYP2D6 substrate.
abobotulinumtoxinA
abobotulinumtoxinA increases effects of desipramine by pharmacodynamic synergism. Use

Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-
containing products may potentiate systemic anticholinergic effects. .
acalabrutinib
desipramine will increase the level or effect of acalabrutinib by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease acalabrutinib dose
to 100 mg once daily if coadministered with a moderate CYP3A inhibitor.
aclidinium
aclidinium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
albuterol
desipramine increases and albuterol decreases sedation. Effect of interaction is not clear,
use caution. Use Caution/Monitor.
alfentanil
alfentanil and desipramine both increase sedation. Use Caution/Monitor.
almotriptan
almotriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
alprazolam
alprazolam and desipramine both increase sedation. Use Caution/Monitor.
altretamine
altretamine increases toxicity of desipramine by unknown mechanism. Use Caution/Monitor.

Increased risk of orthostatic hypotension.
amifampridine
desipramine increases toxicity of amifampridine by Other (see comment). Modify

Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration
with drugs that lower seizure threshold may increase this risk.
amiodarone
amiodarone will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor.
amitriptyline
amitriptyline and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
amitriptyline and desipramine both increase sedation. Use Caution/Monitor.
amobarbital
amobarbital will decrease the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
amobarbital and desipramine both increase sedation. Use Caution/Monitor.
amoxapine
amoxapine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
amoxapine and desipramine both increase sedation. Use Caution/Monitor.
apomorphine
desipramine and apomorphine both increase sedation. Use Caution/Monitor.
aprepitant
aprepitant will increase the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Use Caution/Monitor.
arformoterol
desipramine increases and arformoterol decreases sedation. Effect of interaction is not clear,
aripiprazole
aripiprazole and desipramine both increase sedation. Use Caution/Monitor.

armodafinil
desipramine increases and armodafinil decreases sedation. Effect of interaction is not clear,
asenapine
asenapine will increase the level or effect of desipramine by affecting hepatic enzyme
atazanavir
atazanavir will increase the level or effect of desipramine by affecting hepatic/intestinal

atazanavir increases levels of desipramine by unspecified interaction mechanism. Use

Caution/Monitor.
atropine IV/IM
atropine IV/IM and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
avanafil
desipramine will increase the level or effect of avanafil by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inhibitors may reduce avanafil
clearance increasing systemic exposure to avanafil; increased levels may result in increased
associated adverse events; the maximum recommended dose of STENDRA is 50 mg, not to
exceed once every 24 hours for patients taking concomitant moderate CYP3A4 inhibitors
azelastine
azelastine and desipramine both increase sedation. Use Caution/Monitor.
azithromycin
desipramine and azithromycin both increase QTc interval. Use Caution/Monitor.
baclofen
baclofen and desipramine both increase sedation. Use Caution/Monitor.
bedaquiline
desipramine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely.
ECG should be monitored closely
belladonna and opium
belladonna and opium and desipramine both decrease cholinergic effects/transmission. Use
Caution/Monitor.
belladonna and opium and desipramine both increase sedation. Use Caution/Monitor.
benperidol
benperidol and desipramine both increase sedation. Use Caution/Monitor.
benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, desipramine. Either increases effects of the other by

serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic
neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted,
carefully observe the patient, particularly during treatment initiation and dose adjustment.
benzphetamine
desipramine increases and benzphetamine decreases sedation. Effect of interaction is not

clear, use caution. Use Caution/Monitor.
brexpiprazole
desipramine will increase the level or effect of brexpiprazole by affecting hepatic enzyme
CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole
dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4
inhibitor.
desipramine will increase the level or effect of brexpiprazole by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of
brexpiprazole dose if coadministered with a moderate CYP3A4 inhibitor PLUS a
strong/moderate CYP2D6 inhibitor.
brompheniramine
brompheniramine and desipramine both increase sedation. Use Caution/Monitor.
buprenorphine
buprenorphine and desipramine both increase sedation. Use Caution/Monitor.
buprenorphine buccal
buprenorphine buccal and desipramine both increase sedation. Use Caution/Monitor.
buprenorphine subdermal implant
desipramine will increase the level or effect of buprenorphine subdermal implant by affecting
hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor
patients already on buprenorphine subdermal implant who require newly-initiated treatment
with CYP3A4 inhibitors for signs and symptoms of overmedication. If the dose of the
concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be
necessary and the patient should then be treated with a buprenorphine dosage form that
permits dose adjustments. If a CYP3A4 inhibitor is discontinued in a patient who has been
stabilized on buprenorphine, monitor the patient for withdrawal.
desipramine, buprenorphine subdermal implant. Either increases toxicity of the other by

serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening
serotonin syndrome. If concomitant use is warranted, carefully observe the patient,
particularly during treatment initiation, and during dose adjustment of the serotonergic drug.
Discontinue buprenorphine if serotonin syndrome is suspected.
buprenorphine, long-acting injection
desipramine will increase the level or effect of buprenorphine, long-acting injection by

affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
Patients who transfer to buprenorphine long-acting injection from transmucosal
buprenorphine coadministered with CYP3A4 inhibitors should be monitored to ensure
buprenorphine plasma levels are adequate. Within 2 weeks, if signs and symptoms of
buprenorphine toxicity or overdose occur and the concomitant CYP3A4 inhibitor cannot be
reduced or discontinued, transition the patient back to a buprenorphine formulation that

permits dose adjustments.
desipramine, buprenorphine, long-acting injection. Either increases toxicity of the other by

serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening
serotonin syndrome. If concomitant use is warranted, carefully observe the patient,
particularly during treatment initiation, and during dose adjustment of the serotonergic drug.
Discontinue buprenorphine if serotonin syndrome is suspected.
bupropion
bupropion will increase the level or effect of desipramine by affecting hepatic enzyme
desipramine increases toxicity of bupropion by unspecified interaction mechanism. Use

Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.
butabarbital
butabarbital will decrease the level or effect of desipramine by affecting hepatic/intestinal

butabarbital and desipramine both increase sedation. Use Caution/Monitor.
butalbital
butalbital will decrease the level or effect of desipramine by affecting hepatic/intestinal

butalbital and desipramine both increase sedation. Use Caution/Monitor.
butorphanol
butorphanol and desipramine both increase sedation. Use Caution/Monitor.
cabozantinib
desipramine will increase the level or effect of cabozantinib by affecting hepatic/intestinal

caffeine
desipramine increases and caffeine decreases sedation. Effect of interaction is not clear, use
caution. Use Caution/Monitor.
cannabidiol
desipramine will increase the level or effect of cannabidiol by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the
cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor.
carbamazepine
carbamazepine will decrease the level or effect of desipramine by affecting hepatic/intestinal

carbinoxamine
carbinoxamine and desipramine both increase sedation. Use Caution/Monitor.
carisoprodol
carisoprodol and desipramine both increase sedation. Use Caution/Monitor.
celecoxib
celecoxib will increase the level or effect of desipramine by affecting hepatic enzyme
chloral hydrate
chloral hydrate and desipramine both increase sedation. Use Caution/Monitor.
chlordiazepoxide
chlordiazepoxide and desipramine both increase sedation. Use Caution/Monitor.
chloroquine
chloroquine will increase the level or effect of desipramine by affecting hepatic enzyme
chlorpheniramine
chlorpheniramine and desipramine both increase sedation. Use Caution/Monitor.
chlorpromazine
chlorpromazine and desipramine both increase sedation. Use Caution/Monitor.
chlorzoxazone
chlorzoxazone and desipramine both increase sedation. Use Caution/Monitor.
cimetidine
cimetidine will increase the level or effect of desipramine by affecting hepatic enzyme
cimetidine will increase the level or effect of desipramine by affecting hepatic/intestinal

cinnarizine
cinnarizine and desipramine both increase sedation. Use Caution/Monitor.
clemastine
clemastine and desipramine both increase sedation. Use Caution/Monitor.
clobazam
clobazam will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6
may be required when used concomitantly.
desipramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant

administration can increase the potential for CNS effects (e.g., increased sedation or
respiratory depression).
clomipramine
clomipramine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
clomipramine and desipramine both increase sedation. Use Caution/Monitor.
clonazepam
clonazepam and desipramine both increase sedation. Use Caution/Monitor.
clorazepate
clorazepate and desipramine both increase sedation. Use Caution/Monitor.
clozapine
clozapine and desipramine both increase sedation. Use Caution/Monitor.
cobicistat
cobicistat will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired
effect, including using the lowest feasible initial or maintenance dose, and monitoring for
antidepressant response
cocaine
desipramine and cocaine both increase serotonin levels. Modify Therapy/Monitor Closely.
codeine
codeine and desipramine both increase sedation. Use Caution/Monitor.
desipramine decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism.

Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.
conivaptan
conivaptan will increase the level or effect of desipramine by affecting hepatic/intestinal

crizotinib
crizotinib and desipramine both increase QTc interval. Use Caution/Monitor. ECG monitoring
is recommended, along with drugs that may prolong the QT interval.
cyclizine
cyclizine and desipramine both increase sedation. Use Caution/Monitor.
cyclobenzaprine
cyclobenzaprine and desipramine both increase sedation. Use Caution/Monitor.
cyclosporine
cyclosporine will increase the level or effect of desipramine by affecting hepatic/intestinal

cyproheptadine
cyproheptadine and desipramine both increase sedation. Use Caution/Monitor.
dantrolene
dantrolene and desipramine both increase sedation. Use Caution/Monitor.
darifenacin
darifenacin will increase the level or effect of desipramine by affecting hepatic enzyme
darifenacin will increase the level or effect of desipramine by affecting hepatic/intestinal

darunavir
darunavir will increase the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or
trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest
feasible initial or maintenance dose). Monitor for antidepressant response.
dasatinib
desipramine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.
debrisoquine
desipramine decreases effects of debrisoquine by Other (see comment). Use

Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.
deflazacort
desipramine will increase the level or effect of deflazacort by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease deflazacort dose to
one-third of the recommended dose if coadministered with moderate or strong CYP3A4
inhibitors.
delavirdine
delavirdine will increase the level or effect of desipramine by affecting hepatic/intestinal

desflurane
desflurane and desipramine both increase sedation. Use Caution/Monitor.
desvenlafaxine
desvenlafaxine will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher
desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no
dosage adjustment needed with desvenlafaxine doses <100 mg
deutetrabenazine
desipramine and deutetrabenazine both increase sedation. Use Caution/Monitor.
dexchlorpheniramine
dexchlorpheniramine and desipramine both increase sedation. Use Caution/Monitor.
dexfenfluramine
desipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not

desipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor

Closely.
dexmedetomidine
dexmedetomidine and desipramine both increase sedation. Use Caution/Monitor.
dexmethylphenidate
desipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is

not clear, use caution. Use Caution/Monitor.
dextroamphetamine
desipramine increases and dextroamphetamine decreases sedation. Effect of interaction is

desipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor

Closely.
desipramine increases effects of dextroamphetamine by unknown mechanism. Use

Caution/Monitor.
dextromoramide
dextromoramide and desipramine both increase sedation. Use Caution/Monitor.
diamorphine
diamorphine and desipramine both increase sedation. Use Caution/Monitor.
diazepam
diazepam and desipramine both increase sedation. Use Caution/Monitor.
diethylpropion
desipramine increases and diethylpropion decreases sedation. Effect of interaction is not

difenoxin hcl
difenoxin hcl and desipramine both increase sedation. Use Caution/Monitor.
dihydroergotamine
desipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor

Closely.
dihydroergotamine intranasal
desipramine and dihydroergotamine intranasal both increase serotonin levels. Modify

Therapy/Monitor Closely.
diltiazem
diltiazem will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Use Caution/Monitor.
dimenhydrinate
dimenhydrinate and desipramine both increase sedation. Use Caution/Monitor.
diphenhydramine
diphenhydramine will increase the level or effect of desipramine by affecting hepatic enzyme
diphenhydramine and desipramine both increase sedation. Use Caution/Monitor.
diphenoxylate hcl
diphenoxylate hcl and desipramine both increase sedation. Use Caution/Monitor.
dipipanone
dipipanone and desipramine both increase sedation. Use Caution/Monitor.
dobutamine
desipramine increases and dobutamine decreases sedation. Effect of interaction is not clear,
dolasetron
desipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.
dopamine
desipramine increases and dopamine decreases sedation. Effect of interaction is not clear,
dopexamine
desipramine increases and dopexamine decreases sedation. Effect of interaction is not clear,
dosulepin
desipramine and dosulepin both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and dosulepin both increase sedation. Use Caution/Monitor.
doxepin
desipramine and doxepin both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and doxepin both increase sedation. Use Caution/Monitor.
doxylamine
doxylamine and desipramine both increase sedation. Use Caution/Monitor.

dronedarone
dronedarone will increase the level or effect of desipramine by affecting hepatic enzyme
droperidol
droperidol and desipramine both increase sedation. Use Caution/Monitor.
duloxetine
duloxetine will increase the level or effect of desipramine by affecting hepatic enzyme
eletriptan
eletriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
eliglustat
eliglustat increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism.

Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or
consider reducing the dosage of the concomitant drug and titrate to clinical effect.
elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of desipramine by affecting

hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a
CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations
are associated with serious and/or life-threatening events.
ephedrine
desipramine increases and ephedrine decreases sedation. Effect of interaction is not clear,
desipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.
ephedrine (pulmonary)
desipramine increases and ephedrine (pulmonary) decreases sedation. Effect of interaction

is not clear, use caution. Use Caution/Monitor. .
desipramine increases effects of ephedrine (pulmonary) by unknown mechanism. Use

Caution/Monitor.
epinephrine
desipramine increases and epinephrine decreases sedation. Effect of interaction is not clear,
desipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.
epinephrine inhaled
desipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects,

including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic
antidepressants may potentiate epinephrine effect on cardiovascular system.
epinephrine racemic
desipramine increases and epinephrine racemic decreases sedation. Effect of interaction is

desipramine increases effects of epinephrine racemic by unknown mechanism. Use

Caution/Monitor.
ergotamine
desipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
esketamine intranasal
esketamine intranasal, desipramine. Either increases toxicity of the other by sedation. Modify
estazolam
estazolam and desipramine both increase sedation. Use Caution/Monitor.
ethanol
desipramine and ethanol both increase sedation. Use Caution/Monitor.
ethotoin
ethotoin will decrease the level or effect of desipramine by affecting hepatic/intestinal enzyme
etomidate
etomidate and desipramine both increase sedation. Use Caution/Monitor.
ezogabine
ezogabine, desipramine. Either increases toxicity of the other by QTc interval. Use
Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly
when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is
prescribed with agents known to increase QT interval.
fedratinib
fedratinib will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates
as necessary.
fenfluramine
desipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear,
desipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor

Closely.
flecainide
desipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.
fluoxetine
desipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
fluphenazine
fluphenazine and desipramine both increase sedation. Use Caution/Monitor.
flurazepam
flurazepam and desipramine both increase sedation. Use Caution/Monitor.
fluvoxamine
fluvoxamine will increase the level or effect of desipramine by affecting hepatic/intestinal

desipramine and fluvoxamine both increase QTc interval. Modify Therapy/Monitor Closely.
formoterol
desipramine increases and formoterol decreases sedation. Effect of interaction is not clear,
fosamprenavir
fosamprenavir will increase the level or effect of desipramine by affecting hepatic/intestinal

foscarnet
desipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.
fosphenytoin
fosphenytoin will decrease the level or effect of desipramine by affecting hepatic/intestinal

frovatriptan
frovatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
glycopyrrolate
desipramine increases levels of glycopyrrolate by unknown mechanism. Use

Caution/Monitor.
glycopyrrolate inhaled
desipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use

Caution/Monitor.
glycopyrronium tosylate topical
glycopyrronium tosylate topical, desipramine. Either increases effects of the other by

pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium
tosylate topical with other anticholinergic medications may result in additive anticholinergic
adverse effects.
grapefruit
grapefruit will increase the level or effect of desipramine by affecting hepatic/intestinal

guanfacine
desipramine will increase the level or effect of guanfacine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4
inhibitors significantly increase guanfacine plasma concentrations. FDA-approved labeling for
extended-release (ER) guanfacine recommends that, if coadministered, the guanfacine
dosage should be decreased to half of the recommended dose. Specific recommendations
for immediate-release (IR) guanfacine are not available.
haloperidol
haloperidol and desipramine both increase sedation. Use Caution/Monitor.
henbane
henbane and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
homatropine
homatropine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
huperzine A
huperzine A increases and desipramine decreases cholinergic effects/transmission. Effect of

interaction is not clear, use caution. Use Caution/Monitor.
hydrocodone
hydrocodone, desipramine. Either increases effects of the other by serotonin levels. Use
Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter
system may result in serotonin syndrome. If concomitant use is warranted, carefully observe
the patient, particularly during treatment initiation and dose adjustment.
hydromorphone
hydromorphone and desipramine both increase sedation. Use Caution/Monitor.
hydroxyzine
hydroxyzine and desipramine both increase sedation. Use Caution/Monitor.
hyoscyamine
hyoscyamine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
hyoscyamine spray
hyoscyamine spray and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
ibrutinib
desipramine increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate CYP3A4
inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft
versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of
ibrutinib.
ifosfamide
desipramine will decrease the level or effect of ifosfamide by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Use Caution/Monitor. Use of a CYP3A4 inhibitor may
decrease metabolism of ifosfamide, potentially reducing ifosfamide therapeutic effects.
iloperidone
desipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.
iloperidone and desipramine both increase sedation. Use Caution/Monitor.
imatinib
imatinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6
metabolism. Use Caution/Monitor.
desipramine will increase the level or effect of imatinib by affecting hepatic enzyme CYP2D6
imipramine
desipramine and imipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and imipramine both increase sedation. Use Caution/Monitor.
indacaterol, inhaled
indacaterol, inhaled, desipramine. QTc interval. Use Caution/Monitor. Indacaterol should be

administered with extreme caution to patients treated with TCAs. Drugs that are known to
prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
indinavir
indinavir will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme
ipratropium
ipratropium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at
regularly recommended dosages.
irinotecan
desipramine will increase the level or effect of irinotecan by affecting hepatic/intestinal

irinotecan liposomal
desipramine will increase the level or effect of irinotecan liposomal by affecting

hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
isoniazid
desipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.
isoproterenol
desipramine increases and isoproterenol decreases sedation. Effect of interaction is not

ivacaftor
desipramine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Use Caution/Monitor. Reduce ivacaftor dose to 150 mg once daily when
coadministered with moderate CYP3A4 inhibitors.
ivosidenib
desipramine will increase the level or effect of ivosidenib by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with moderate
CYP3A4 inhibitors may increase ivosidenib plasma concentrations, thus increasing the risk of
QTc prolongation. Monitor for increased risk of QTc interval prolongation.
ketamine
ketamine and desipramine both increase sedation. Use Caution/Monitor.
ketoconazole
ketoconazole will increase the level or effect of desipramine by affecting hepatic/intestinal

ketotifen, ophthalmic
desipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
L-tryptophan
desipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor

Closely.
lapatinib
desipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.
levalbuterol
desipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear,
levofloxacin
desipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
levorphanol
levorphanol and desipramine both increase sedation. Use Caution/Monitor.
lisdexamfetamine
desipramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not

lithium
desipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.
lofepramine
desipramine and lofepramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and lofepramine both increase sedation. Use Caution/Monitor.
lofexidine
desipramine and lofexidine both increase sedation. Use Caution/Monitor.
desipramine decreases effects of lofexidine by unspecified interaction mechanism. Use

Caution/Monitor.
loprazolam
loprazolam and desipramine both increase sedation. Use Caution/Monitor.
lorazepam
lorazepam and desipramine both increase sedation. Use Caution/Monitor.
lorcaserin
lorcaserin will increase the level or effect of desipramine by affecting hepatic enzyme
lormetazepam
lormetazepam and desipramine both increase sedation. Use Caution/Monitor.
loxapine
loxapine and desipramine both increase sedation. Use Caution/Monitor.
loxapine inhaled
loxapine inhaled and desipramine both increase sedation. Use Caution/Monitor.
lsd
desipramine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.
lurasidone
lurasidone increases effects of desipramine by Other (see comment). Use Caution/Monitor.

Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood
pressure and adjust dose of antihypertensive agent as needed.
maprotiline
desipramine and maprotiline both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and maprotiline both increase sedation. Use Caution/Monitor.
maraviroc
maraviroc will increase the level or effect of desipramine by affecting hepatic enzyme
marijuana
marijuana will increase the level or effect of desipramine by affecting hepatic enzyme
desipramine and marijuana both increase sedation. Use Caution/Monitor.
meclizine
meclizine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
mefloquine
desipramine will increase the level or effect of mefloquine by affecting hepatic/intestinal

melatonin
desipramine and melatonin both increase sedation. Use Caution/Monitor.
meperidine
meperidine and desipramine both increase sedation. Use Caution/Monitor.
meprobamate
desipramine and meprobamate both increase sedation. Use Caution/Monitor.
metaproterenol
desipramine increases and metaproterenol decreases sedation. Effect of interaction is not

metaxalone
metaxalone and desipramine both increase sedation. Use Caution/Monitor.
methadone
desipramine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.
methadone and desipramine both increase sedation. Use Caution/Monitor.
methamphetamine
desipramine increases and methamphetamine decreases sedation. Effect of interaction is not

methocarbamol
methocarbamol and desipramine both increase sedation. Use Caution/Monitor.
methscopolamine
methscopolamine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
methylenedioxymethamphetamine
desipramine increases and methylenedioxymethamphetamine decreases sedation. Effect of

interaction is not clear, use caution. Use Caution/Monitor.
methylphenidate
desipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment:

midazolam
midazolam and desipramine both increase sedation. Use Caution/Monitor.
midazolam intranasal
midazolam intranasal, desipramine. Either increases effects of the other by

pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of
barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation,
airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged
drug effect.
midodrine
desipramine increases and midodrine decreases sedation. Effect of interaction is not clear,
mifepristone
mifepristone, desipramine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if

available.
mirabegron
mirabegron will increase the level or effect of desipramine by affecting hepatic enzyme
mirtazapine
desipramine and mirtazapine both increase sedation. Use Caution/Monitor.
desipramine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.
modafinil
desipramine increases and modafinil decreases sedation. Effect of interaction is not clear,
morphine
morphine and desipramine both increase sedation. Use Caution/Monitor.
desipramine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.
motherwort
desipramine and motherwort both increase sedation. Use Caution/Monitor.
moxonidine
desipramine and moxonidine both increase sedation. Use Caution/Monitor.

nabilone
desipramine and nabilone both increase sedation. Use Caution/Monitor.
nalbuphine
nalbuphine and desipramine both increase sedation. Use Caution/Monitor.
naldemedine
desipramine increases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if
coadministered with strong or moderate CYP3A4 inhibitors.
naratriptan
naratriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
nefopam
nefopam, desipramine. Mechanism: unspecified interaction mechanism. Use

Caution/Monitor. Use combination with caution.
nelfinavir
nelfinavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6
nifedipine
nifedipine will increase the level or effect of desipramine by affecting hepatic/intestinal

nilotinib
nilotinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6
norepinephrine
desipramine increases and norepinephrine decreases sedation. Effect of interaction is not

desipramine increases effects of norepinephrine by unknown mechanism. Use

Caution/Monitor.
nortriptyline
desipramine and nortriptyline both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and nortriptyline both increase sedation. Use Caution/Monitor.
ofloxacin
desipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
olanzapine
olanzapine and desipramine both increase sedation. Use Caution/Monitor.

olodaterol inhaled
desipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs
prolong the QTc interval and may potentiate the effects of beta2 agonists on the
cardiovascular system; increased risk of ventricular arrhythmias
opium tincture
opium tincture and desipramine both increase sedation. Use Caution/Monitor.
orphenadrine
desipramine and orphenadrine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
orphenadrine and desipramine both increase sedation. Use Caution/Monitor.
osimertinib
osimertinib and desipramine both increase QTc interval. Use Caution/Monitor. Conduct
periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the
QTc interval.
oxazepam
oxazepam and desipramine both increase sedation. Use Caution/Monitor.
oxybutynin
oxybutynin and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
oxybutynin topical
oxybutynin topical and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
oxybutynin transdermal
oxybutynin transdermal and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
oxycodone
oxycodone and desipramine both increase sedation. Use Caution/Monitor.
oxymetazoline intranasal
desipramine increases effects of oxymetazoline intranasal by pharmacodynamic synergism.

Use Caution/Monitor. TCAs inhibit norepinephrine uptake in adrenergic neurons, thereby
increasing synaptic norepinephrine levels. Coadministration with alpha1 agonists may cause
increased adrenergic receptor stimulation. When oxymetazoline is combined with intranasal
tetracaine for dental anesthesia, avoid or use alternant anesthetic in patients taking TCAs.
oxymorphone
oxymorphone and desipramine both increase sedation. Use Caution/Monitor.
palbociclib
desipramine will increase the level or effect of palbociclib by affecting hepatic/intestinal

paliperidone
desipramine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.
paliperidone and desipramine both increase sedation. Use Caution/Monitor.
pancuronium
pancuronium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
panobinostat
panobinostat will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor. Panobinostat can increase the levels and effects
of sensitive CYP2D6 substrates or those with a narrow therapeutic index CYP2D6.
papaveretum
papaveretum and desipramine both increase sedation. Use Caution/Monitor.
papaverine
desipramine and papaverine both increase sedation. Use Caution/Monitor.
parecoxib
parecoxib will increase the level or effect of desipramine by affecting hepatic enzyme
paroxetine
desipramine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.
pasireotide
desipramine and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
pazopanib
desipramine and pazopanib both increase QTc interval. Use Caution/Monitor.
peginterferon alfa 2b
peginterferon alfa 2b, desipramine. Other (see comment). Use Caution/Monitor. Comment:
When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the
therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or
decrease levels of CYP2D6 substrate.
pentazocine
pentazocine and desipramine both increase sedation. Use Caution/Monitor.
desipramine and pentazocine both increase serotonin levels. Modify Therapy/Monitor

Closely.
pentobarbital
pentobarbital will decrease the level or effect of desipramine by affecting hepatic/intestinal

pentobarbital and desipramine both increase sedation. Use Caution/Monitor.
perphenazine
perphenazine will increase the level or effect of desipramine by affecting hepatic enzyme
perphenazine and desipramine both increase sedation. Use Caution/Monitor.
phendimetrazine
desipramine increases and phendimetrazine decreases sedation. Effect of interaction is not

phenobarbital
phenobarbital will decrease the level or effect of desipramine by affecting hepatic/intestinal

phenobarbital and desipramine both increase sedation. Use Caution/Monitor.
phentermine
desipramine increases and phentermine decreases sedation. Effect of interaction is not clear,
phenylephrine
desipramine increases and phenylephrine decreases sedation. Effect of interaction is not

phenylephrine ophthalmic
desipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor.

neuron.
phenylephrine PO
desipramine increases and phenylephrine PO decreases sedation. Effect of interaction is not

clear, use caution. Use Caution/Monitor. .
phenytoin
phenytoin will decrease the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider phenytoin serum levels if a
tricyclic antidepressant is added to therapy or if the patient begins to exhibit signs of toxicity;
lower doses of phenytoin may be required. If phenytoin is added to tricyclic antidepressant
therapy, monitor for clinical efficacy of the tricyclic agent. Tricyclic antidepressants when
given concomitantly with anticonvulsants can increase CNS depression.
pholcodine
desipramine and pholcodine both increase sedation. Use Caution/Monitor.
pimozide
pimozide and desipramine both increase sedation. Use Caution/Monitor.
pirbuterol
desipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear,
posaconazole
desipramine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.
pralidoxime
pralidoxime and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
primidone
primidone will decrease the level or effect of desipramine by affecting hepatic/intestinal

primidone and desipramine both increase sedation. Use Caution/Monitor.
prochlorperazine
prochlorperazine and desipramine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and desipramine both increase sedation. Use Caution/Monitor.
promethazine
promethazine and desipramine both increase QTc interval. Use Caution/Monitor.
promethazine and desipramine both increase sedation. Use Caution/Monitor.
propafenone
propafenone will increase the level or effect of desipramine by affecting hepatic enzyme
propantheline
propantheline and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
propofol
propofol and desipramine both increase sedation. Use Caution/Monitor.
propylhexedrine
desipramine increases and propylhexedrine decreases sedation. Effect of interaction is not

protriptyline
desipramine and protriptyline both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and protriptyline both increase sedation. Use Caution/Monitor.

pseudoephedrine
desipramine increases and pseudoephedrine decreases sedation. Effect of interaction is not

quazepam
quazepam and desipramine both increase sedation. Use Caution/Monitor.
quetiapine
quetiapine and desipramine both increase sedation. Use Caution/Monitor.
quetiapine, desipramine. Either increases toxicity of the other by QTc interval. Use
Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for
prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients
with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quinacrine
quinacrine will increase the level or effect of desipramine by affecting hepatic enzyme
quinine
desipramine and quinine both increase QTc interval. Use Caution/Monitor.
ramelteon
desipramine and ramelteon both increase sedation. Use Caution/Monitor.
ranolazine
ranolazine will increase the level or effect of desipramine by affecting hepatic enzyme
desipramine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.
rapacuronium
rapacuronium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
rifabutin
rifabutin will decrease the level or effect of desipramine by affecting hepatic/intestinal enzyme
rifabutin decreases levels of desipramine by increasing metabolism. Use Caution/Monitor.
rifampin
rifampin will decrease the level or effect of desipramine by affecting hepatic/intestinal enzyme
rifapentine
rifapentine will decrease the level or effect of desipramine by affecting hepatic/intestinal

rilpivirine
rilpivirine increases toxicity of desipramine by QTc interval. Use Caution/Monitor. Rilpivirine

should be used with caution when co-administered with a drug with a known risk of Torsades
de Pointes.
risperidone
desipramine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.
risperidone and desipramine both increase sedation. Use Caution/Monitor.
ritonavir
ritonavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6
ritonavir will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme
rizatriptan
rizatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
rocuronium
rocuronium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
rolapitant
rolapitant will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations
of CYP2D6 substrates for at least 28 days following rolapitant administration.
romidepsin
desipramine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.
ruxolitinib
desipramine will increase the level or effect of ruxolitinib by affecting hepatic/intestinal

salmeterol
desipramine increases and salmeterol decreases sedation. Effect of interaction is not clear,
SAMe
desipramine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.
scopolamine
scopolamine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
scullcap
desipramine and scullcap both increase sedation. Use Caution/Monitor.
secobarbital
secobarbital will decrease the level or effect of desipramine by affecting hepatic/intestinal

secobarbital and desipramine both increase sedation. Use Caution/Monitor.
sertraline
sertraline will increase the level or effect of desipramine by affecting hepatic enzyme
CYP2D6 metabolism. Modify Therapy/Monitor Closely.
sevoflurane
sevoflurane and desipramine both increase sedation. Use Caution/Monitor.
shepherd's purse
desipramine and shepherd's purse both increase sedation. Use Caution/Monitor.
sodium sulfate/potassium sulfate/magnesium sulfate
desipramine, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment).

Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause
SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.
sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol
desipramine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other

(see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with
drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte
imbalance.
solifenacin
solifenacin and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
sonidegib
desipramine will increase the level or effect of sonidegib by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of
sonidegib with moderate CYP3A4 inhibitors. If a moderate CYP3A inhibitor must be used,
administer the moderate CYP3A inhibitor for <14 days and monitor closely for adverse
reactions, particularly musculoskeletal adverse reactions.
sorafenib
sorafenib and desipramine both increase QTc interval. Use Caution/Monitor.
St John's Wort
St John's Wort will decrease the level or effect of desipramine by affecting hepatic/intestinal
stiripentol
stiripentol, desipramine. Either increases effects of the other by sedation. Use

Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol,
may increase the risk of sedation and somnolence.
sufentanil
sufentanil and desipramine both increase sedation. Use Caution/Monitor.
sufentanil SL
sufentanil SL, desipramine. Either increases effects of the other by serotonin levels. Use
Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter
system may result in serotonin syndrome. If concomitant use is warranted, carefully observe
the patient, particularly during treatment initiation and dose adjustment.
desipramine will increase the level or effect of sufentanil SL by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of sufentanil SL with
any CYP3A4 inhibitor may increase sufentanil plasma concentration, and, thereby increase
or prolonged adverse effects, including potentially fatal respiratory depression.
sulfamethoxazole
desipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor

Closely.
sumatriptan
sumatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
sumatriptan intranasal
sumatriptan intranasal and desipramine both increase serotonin levels. Modify

sumatriptan transdermal
sumatriptan transdermal and desipramine both increase serotonin levels. Modify

suvorexant
suvorexant and desipramine both increase sedation. Modify Therapy/Monitor Closely.

Dosage adjustments of suvorexant and concomitant CNS depressants may be necessary
desipramine will increase the level or effect of suvorexant by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease suvorexant starting
dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors
tadalafil
desipramine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inhibitors may reduce tadalafil
clearance increasing systemic exposure to tadalafil; increased levels may result in increased
associated adverse events.
tamsulosin
desipramine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs
that are predominantly metabolized by CYP3A.
desipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6

tapentadol
tapentadol and desipramine both increase sedation. Use Caution/Monitor.
desipramine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.
telavancin
desipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
temazepam
temazepam and desipramine both increase sedation. Use Caution/Monitor.
terbutaline
desipramine increases and terbutaline decreases sedation. Effect of interaction is not clear,
tezacaftor
desipramine will increase the level or effect of tezacaftor by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust tezacaftor dosage
regimen if coadministered with a moderate CYP3A inhibitor.
thioridazine
thioridazine and desipramine both increase sedation. Use Caution/Monitor.
thiothixene
thiothixene and desipramine both increase sedation. Use Caution/Monitor.
tinidazole
desipramine will increase the level or effect of tinidazole by affecting hepatic/intestinal

tiotropium
tiotropium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
tipranavir
tipranavir will increase the level or effect of desipramine by affecting hepatic enzyme
tofacitinib
desipramine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4

metabolism. Use Caution/Monitor. No specific dose adjustment recommended when
tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if
coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.
tolterodine
tolterodine and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
topiramate
desipramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
trabectedin
desipramine will increase the level or effect of trabectedin by affecting hepatic/intestinal

tramadol
tramadol and desipramine both increase sedation. Use Caution/Monitor.
desipramine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.
trazodone
desipramine and trazodone both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and trazodone both increase sedation. Use Caution/Monitor.
triazolam
triazolam and desipramine both increase sedation. Use Caution/Monitor.
triclofos
triclofos and desipramine both increase sedation. Use Caution/Monitor.
trifluoperazine
trifluoperazine and desipramine both increase sedation. Use Caution/Monitor.
trihexyphenidyl
trihexyphenidyl and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor. Potential for additive anticholinergic effects.
trimethoprim
desipramine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.
trimipramine
desipramine and trimipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
desipramine and trimipramine both increase sedation. Use Caution/Monitor.
triprolidine
triprolidine and desipramine both increase sedation. Use Caution/Monitor.
tropisetron
desipramine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.
trospium chloride
trospium chloride and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
valerian
valerian and desipramine both increase sedation. Use Caution/Monitor.
vecuronium
vecuronium and desipramine both decrease cholinergic effects/transmission. Use

Caution/Monitor.
venlafaxine
venlafaxine will increase the level or effect of desipramine by affecting hepatic enzyme
desipramine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.
verapamil
verapamil will increase the level or effect of desipramine by affecting hepatic/intestinal

voriconazole
desipramine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.
xylometazoline
desipramine increases and xylometazoline decreases sedation. Effect of interaction is not

yohimbine
desipramine increases and yohimbine decreases sedation. Effect of interaction is not clear,
ziconotide
desipramine and ziconotide both increase sedation. Use Caution/Monitor.
ziprasidone
ziprasidone and desipramine both increase sedation. Use Caution/Monitor.
zolmitriptan
zolmitriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
Minor (132)
acarbose
desipramine increases effects of acarbose by pharmacodynamic synergism.

Minor/Significance Unknown.
amobarbital
amobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

Barbiturates may increase adverse effects, including respiratory depression, produced by
toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and
decrease blood concentrations of TCAs.
anticholinergic/sedative combos
anticholinergic/sedative combos and desipramine both decrease cholinergic

effects/transmission. Minor/Significance Unknown.
armodafinil
armodafinil will decrease the level or effect of desipramine by affecting hepatic/intestinal

enzyme CYP3A4 metabolism. Minor/Significance Unknown.
artemether/lumefantrine
artemether/lumefantrine will decrease the level or effect of desipramine by affecting

hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
atracurium
atracurium and desipramine both decrease cholinergic effects/transmission.

atropine
atropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance

Unknown.
desipramine increases levels of atropine by unknown mechanism. Minor/Significance

Unknown.
atropine IV/IM
desipramine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance

Unknown.
bazedoxifene/conjugated estrogens
bazedoxifene/conjugated estrogens, desipramine. Mechanism: unspecified interaction

mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic
antidepressant effects, while increasing TCA plasma concentration and adverse effects.
belladonna alkaloids
belladonna alkaloids and desipramine both decrease cholinergic effects/transmission.

benztropine
benztropine and desipramine both decrease cholinergic effects/transmission.

bethanechol
bethanechol increases and desipramine decreases cholinergic effects/transmission. Effect of

interaction is not clear, use caution. Minor/Significance Unknown.
bosentan
bosentan will decrease the level or effect of desipramine by affecting hepatic/intestinal

brimonidine
desipramine decreases effects of brimonidine by pharmacodynamic antagonism.

budesonide
budesonide will decrease the level or effect of desipramine by affecting hepatic/intestinal

butabarbital
butabarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

butalbital
butalbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

carbachol
carbachol increases and desipramine decreases cholinergic effects/transmission. Effect of

carbamazepine
carbamazepine decreases levels of desipramine by increasing metabolism.

cevimeline
cevimeline increases and desipramine decreases cholinergic effects/transmission. Effect of

chlorpromazine
desipramine, chlorpromazine. Either increases levels of the other by decreasing metabolism.

Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, chlorpromazine. Either increases levels of the other by pharmacodynamic

synergism. Minor/Significance Unknown. Additive anticholinergic effects.
chlorpropamide
desipramine increases effects of chlorpropamide by pharmacodynamic synergism.

cisatracurium
cisatracurium and desipramine both decrease cholinergic effects/transmission.

conjugated estrogens
conjugated estrogens, desipramine. Mechanism: unspecified interaction mechanism.

Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant
effects, while increasing TCA plasma concentration and adverse effects.
conjugated estrogens, vaginal
conjugated estrogens, vaginal, desipramine. Mechanism: unspecified interaction mechanism.

cortisone
cortisone will decrease the level or effect of desipramine by affecting hepatic/intestinal

cyclizine
cyclizine and desipramine both decrease cholinergic effects/transmission. Minor/Significance

Unknown.
cyclobenzaprine
cyclobenzaprine and desipramine both decrease cholinergic effects/transmission.

darifenacin
darifenacin and desipramine both decrease cholinergic effects/transmission.

desflurane
desflurane, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

Unknown. Risk of arrhythmias or hypotension.
dexamethasone
dexamethasone will decrease the level or effect of desipramine by affecting hepatic/intestinal

dexmethylphenidate
dexmethylphenidate increases effects of desipramine by decreasing metabolism.

DHEA, herbal
DHEA, herbal will increase the level or effect of desipramine by affecting hepatic/intestinal
dicyclomine
dicyclomine and desipramine both decrease cholinergic effects/transmission.

diphenhydramine
diphenhydramine and desipramine both decrease cholinergic effects/transmission.

desipramine and diphenhydramine both decrease cholinergic effects/transmission.

donepezil
donepezil increases and desipramine decreases cholinergic effects/transmission. Effect of

echothiophate iodide
echothiophate iodide increases and desipramine decreases cholinergic effects/transmission.

Effect of interaction is not clear, use caution. Minor/Significance Unknown.
efavirenz
efavirenz will decrease the level or effect of desipramine by affecting hepatic/intestinal

eslicarbazepine acetate
eslicarbazepine acetate will decrease the level or effect of desipramine by affecting

estradiol
estradiol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while
increasing TCA plasma concentration and adverse effects.
estradiol vaginal
desipramine will increase the level or effect of estradiol vaginal by affecting hepatic/intestinal
estrogens conjugated synthetic
estrogens conjugated synthetic, desipramine. Mechanism: unspecified interaction

estrogens esterified
estrogens esterified, desipramine. Mechanism: unspecified interaction mechanism.

Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic
antidepressants. However, interactions are not common.
estropipate
estropipate, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

ethanol
ethanol decreases levels of desipramine by increasing metabolism. Minor/Significance

Unknown. Interaction esp. seen in detoxified alcoholics.
ethinylestradiol
ethinylestradiol, desipramine. Mechanism: unspecified interaction mechanism.

Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl
estradiol. Increased antidepressant serum concentrations may occur. Potential for increased
TCA adverse effects.
etomidate
etomidate, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

etravirine
etravirine will decrease the level or effect of desipramine by affecting hepatic/intestinal

eucalyptus
eucalyptus will decrease the level or effect of desipramine by affecting hepatic/intestinal

desipramine and eucalyptus both increase sedation. Minor/Significance Unknown.
fesoterodine
fesoterodine and desipramine both decrease cholinergic effects/transmission.

flavoxate
flavoxate and desipramine both decrease cholinergic effects/transmission. Minor/Significance

Unknown.
fludrocortisone
fludrocortisone will decrease the level or effect of desipramine by affecting hepatic/intestinal

fluphenazine
desipramine, fluphenazine. Either increases levels of the other by decreasing metabolism.

desipramine, fluphenazine. Either increases levels of the other by pharmacodynamic

galantamine
galantamine increases and desipramine decreases cholinergic effects/transmission. Effect of

glimepiride
desipramine increases effects of glimepiride by pharmacodynamic synergism.

glipizide
desipramine increases effects of glipizide by pharmacodynamic synergism.

glyburide
desipramine increases effects of glyburide by pharmacodynamic synergism.

glycopyrrolate
glycopyrrolate and desipramine both decrease cholinergic effects/transmission.

glycopyrrolate inhaled
glycopyrrolate inhaled and desipramine both decrease cholinergic effects/transmission.

griseofulvin
griseofulvin will decrease the level or effect of desipramine by affecting hepatic/intestinal

hydrocortisone
hydrocortisone will decrease the level or effect of desipramine by affecting hepatic/intestinal

hydroxyprogesterone caproate
hydroxyprogesterone caproate, desipramine. Mechanism: unspecified interaction

insulin aspart
desipramine increases effects of insulin aspart by pharmacodynamic synergism.

insulin detemir
desipramine increases effects of insulin detemir by pharmacodynamic synergism.

insulin glargine
desipramine increases effects of insulin glargine by pharmacodynamic synergism.

insulin glulisine
desipramine increases effects of insulin glulisine by pharmacodynamic synergism.

insulin lispro
desipramine increases effects of insulin lispro by pharmacodynamic synergism.

insulin NPH
desipramine increases effects of insulin NPH by pharmacodynamic synergism.

insulin regular human
desipramine increases effects of insulin regular human by pharmacodynamic synergism.

isoniazid
isoniazid will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme
CYP3A4 metabolism. Minor/Significance Unknown.
isoproterenol
isoproterenol, desipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of

cardiac arrhythmias.
ketamine
ketamine, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

lapatinib
lapatinib will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme
lithium
lithium, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Risk of

neurotoxicity in geriatric pts. Multiple mechanisms involved.
lumefantrine
lumefantrine will decrease the level or effect of desipramine by affecting hepatic/intestinal

marijuana
marijuana will increase the level or effect of desipramine by affecting hepatic/intestinal

mestranol
mestranol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

metformin
desipramine increases effects of metformin by pharmacodynamic synergism.

methylprednisolone
methylprednisolone will decrease the level or effect of desipramine by affecting

metronidazole
metronidazole will increase the level or effect of desipramine by affecting hepatic/intestinal

miconazole vaginal
miconazole vaginal will increase the level or effect of desipramine by affecting

miglitol
desipramine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance

Unknown.
modafinil
modafinil will decrease the level or effect of desipramine by affecting hepatic/intestinal

nateglinide
desipramine increases effects of nateglinide by pharmacodynamic synergism.

neostigmine
neostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of

nevirapine
nevirapine will decrease the level or effect of desipramine by affecting hepatic/intestinal

nilotinib
nilotinib will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme
onabotulinumtoxinA
onabotulinumtoxinA and desipramine both decrease cholinergic effects/transmission.

oxcarbazepine
oxcarbazepine will decrease the level or effect of desipramine by affecting hepatic/intestinal

oxiconazole
oxiconazole will increase the level or effect of desipramine by affecting hepatic/intestinal

panax ginseng
panax ginseng increases effects of desipramine by pharmacodynamic synergism.

pentobarbital
pentobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

perphenazine
desipramine, perphenazine. Either increases levels of the other by decreasing metabolism.

desipramine, perphenazine. Either increases levels of the other by pharmacodynamic

phenobarbital
phenobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

physostigmine
physostigmine increases and desipramine decreases cholinergic effects/transmission. Effect

of interaction is not clear, use caution. Minor/Significance Unknown.
pilocarpine
pilocarpine increases and desipramine decreases cholinergic effects/transmission. Effect of

pilocarpine ophthalmic
pilocarpine ophthalmic increases and desipramine decreases cholinergic

effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance
Unknown.
pioglitazone
desipramine increases effects of pioglitazone by pharmacodynamic synergism.

pleurisy root
pleurisy root decreases effects of desipramine by unspecified interaction mechanism.

Minor/Significance Unknown. Theoretical interaction.
posaconazole
posaconazole will increase the level or effect of desipramine by affecting hepatic/intestinal

prednisolone
prednisolone will decrease the level or effect of desipramine by affecting hepatic/intestinal

prednisone
prednisone will decrease the level or effect of desipramine by affecting hepatic/intestinal

primidone
primidone, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

prochlorperazine
desipramine, prochlorperazine. Either increases levels of the other by decreasing

metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic

progesterone micronized
progesterone micronized, desipramine. Mechanism: unspecified interaction mechanism.

promazine
desipramine, promazine. Either increases levels of the other by decreasing metabolism.

desipramine, promazine. Either increases levels of the other by pharmacodynamic

promethazine
desipramine, promethazine. Either increases levels of the other by decreasing metabolism.

desipramine, promethazine. Either increases levels of the other by pharmacodynamic

propofol
propofol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance

pyridostigmine
pyridostigmine increases and desipramine decreases cholinergic effects/transmission. Effect

quinupristin/dalfopristin
quinupristin/dalfopristin will increase the level or effect of desipramine by affecting

repaglinide
desipramine increases effects of repaglinide by pharmacodynamic synergism.

rivastigmine
rivastigmine increases and desipramine decreases cholinergic effects/transmission. Effect of

rosiglitazone
desipramine increases effects of rosiglitazone by pharmacodynamic synergism.

rufinamide
rufinamide will decrease the level or effect of desipramine by affecting hepatic/intestinal

sage
desipramine and sage both increase sedation. Minor/Significance Unknown.
saxagliptin
desipramine increases effects of saxagliptin by pharmacodynamic synergism.

secobarbital
secobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment:

sevoflurane
sevoflurane, desipramine. Mechanism: unspecified interaction mechanism.

Minor/Significance Unknown. Risk of arrhythmias or hypotension.
sitagliptin
desipramine increases effects of sitagliptin by pharmacodynamic synergism.

succinylcholine
succinylcholine increases and desipramine decreases cholinergic effects/transmission. Effect

sulfamethoxazole
sulfamethoxazole decreases levels of desipramine by unspecified interaction mechanism.

thioridazine
desipramine, thioridazine. Either increases levels of the other by decreasing metabolism.

desipramine, thioridazine. Either increases levels of the other by pharmacodynamic

tolazamide
desipramine increases effects of tolazamide by pharmacodynamic synergism.

tolbutamide
desipramine increases effects of tolbutamide by pharmacodynamic synergism.

topiramate
topiramate will decrease the level or effect of desipramine by affecting hepatic/intestinal

trifluoperazine
desipramine, trifluoperazine. Either increases levels of the other by decreasing metabolism.

desipramine, trifluoperazine. Either increases levels of the other by pharmacodynamic

vasopressin
desipramine increases effects of vasopressin by pharmacodynamic synergism.

verapamil
verapamil increases levels of desipramine by decreasing metabolism. Minor/Significance

Unknown.
vildagliptin
desipramine increases effects of vildagliptin by pharmacodynamic synergism.

voriconazole
voriconazole will increase the level or effect of desipramine by affecting hepatic/intestinal

zafirlukast
zafirlukast will increase the level or effect of desipramine by affecting hepatic/intestinal

zolpidem
zolpidem, desipramine. Either increases effects of the other by pharmacodynamic synergism.

Minor/Significance Unknown. Additive CNS depression.

Desipramine (RX) : Interactions

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Desipramine (RX) : Interactions

Uploaded by

Copyright:

Available Formats

1/10/2019 Norpramin (desipramine) dosing, indications, interactions, adverse effects, and more

This site is intended for healthcare professionals

Enter a drug name and desipramine

Serious - Use Alternative

Significant - Monitor Closely

All Interactions Sort By: Severity

desipramine and cisapride both increase QTc interval. Contraindicated.

desipramine and disopyramide both increase QTc interval. Contraindicated.

dronedarone will increase the level or effect of desipramine by affecting hepatic/intestinal

desipramine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism.

eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate

desipramine will increase the level or effect of flibanserin by affecting hepatic/intestinal

desipramine and ibutilide both increase QTc interval. Contraindicated.

desipramine and indapamide both increase QTc interval. Contraindicated.

desipramine decreases effects of iobenguane I 123 by pharmacodynamic antagonism.

isocarboxazid and desipramine both increase serotonin levels. Contraindicated.

desipramine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4

desipramine and pentamidine both increase QTc interval. Contraindicated.

phenelzine and desipramine both increase serotonin levels. Contraindicated.

desipramine and pimozide both increase QTc interval. Contraindicated.

desipramine and procainamide both increase QTc interval. Contraindicated.

procarbazine and desipramine both increase serotonin levels. Contraindicated. Combination

quinidine and desipramine both increase QTc interval. Contraindicated.

desipramine, safinamide. Either increases toxicity of the other by serotonin levels.

desipramine and sotalol both increase QTc interval. Contraindicated.

tranylcypromine and desipramine both increase serotonin levels. Contraindicated.

Serious - Use Alternative (137)

artemether/lumefantrine will increase the level or effect of desipramine by affecting hepatic

desipramine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4

desipramine increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4

clarithromycin will increase the level or effect of desipramine by affecting hepatic/intestinal

desipramine will increase the level or effect of cobimetinib by affecting hepatic/intestinal

dasatinib will increase the level or effect of desipramine by affecting hepatic/intestinal

desipramine, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug.

desipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug.

desipramine increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4

desipramine will increase the level or effect of entrectinib by affecting hepatic/intestinal

erythromycin base will increase the level or effect of desipramine by affecting

erythromycin ethylsuccinate will increase the level or effect of desipramine by affecting

erythromycin lactobionate will increase the level or effect of desipramine by affecting

erythromycin stearate will increase the level or effect of desipramine by affecting

desipramine will increase the level or effect of fentanyl intranasal by affecting

fentanyl iontophoretic transdermal system

desipramine will increase the level or effect of fentanyl transdermal by affecting

desipramine will increase the level or effect of fentanyl transmucosal by affecting

fluconazole will increase the level or effect of desipramine by affecting hepatic/intestinal

fosamprenavir increases levels of desipramine by decreasing metabolism. Avoid or Use

desipramine decreases effects of guanfacine by Other (see comment). Avoid or Use

desipramine will increase the level or effect of ivabradine by affecting hepatic/intestinal

desipramine, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug.

desipramine, methamphetamine. Other (see comment). Avoid or Use Alternate Drug.

desipramine, methylenedioxymethamphetamine. Other (see comment). Avoid or Use

desipramine will increase the level or effect of midazolam intranasal by affecting

desipramine will increase the level or effect of naloxegol by affecting hepatic/intestinal

nefazodone will increase the level or effect of desipramine by affecting hepatic/intestinal

netupitant/palonosetron, desipramine. Either increases toxicity of the other by serotonin

desipramine, phendimetrazine. Other (see comment). Avoid or Use Alternate Drug.

desipramine, pseudoephedrine. Other (see comment). Avoid or Use Alternate Drug.

desipramine will increase the level or effect of siponimod by affecting hepatic/intestinal

desipramine, sodium oxybate. Either increases effects of the other by pharmacodynamic

tedizolid, desipramine. Either increases effects of the other by Mechanism:

umeclidinium bromide/vilanterol inhaled